ME02675B - Novi derivati cikloheksilamina sa aktivnostima beta2 adrenergijskog agonista i m3 muscarinskog antagonista - Google Patents
Novi derivati cikloheksilamina sa aktivnostima beta2 adrenergijskog agonista i m3 muscarinskog antagonistaInfo
- Publication number
- ME02675B ME02675B MEP-2017-18A MEP1817A ME02675B ME 02675 B ME02675 B ME 02675B ME P1817 A MEP1817 A ME P1817A ME 02675 B ME02675 B ME 02675B
- Authority
- ME
- Montenegro
- Prior art keywords
- hydroxy
- amino
- methyl
- group
- ethyl
- Prior art date
Links
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 title 1
- 239000000556 agonist Substances 0.000 title 1
- 230000003042 antagnostic effect Effects 0.000 title 1
- 150000003946 cyclohexylamines Chemical class 0.000 title 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 32
- -1 cyclohexyl hydroxy(di-2-thienyl)acetate Chemical compound 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 9
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 claims 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims 6
- 125000004430 oxygen atom Chemical group O* 0.000 claims 6
- 125000001544 thienyl group Chemical group 0.000 claims 6
- 229910052801 chlorine Inorganic materials 0.000 claims 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 5
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 4
- 125000001309 chloro group Chemical group Cl* 0.000 claims 4
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 4
- 239000012453 solvate Substances 0.000 claims 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims 3
- 235000019253 formic acid Nutrition 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 2
- 229910052731 fluorine Inorganic materials 0.000 claims 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- FVEJUHUCFCAYRP-UHFFFAOYSA-N 2-hydroxy-2,2-dithiophen-2-ylacetic acid Chemical compound C=1C=CSC=1C(O)(C(=O)O)C1=CC=CS1 FVEJUHUCFCAYRP-UHFFFAOYSA-N 0.000 claims 1
- WCRHWWWLTNWHQS-ABCZBHHISA-N C12=CC=CC=C2OC2=CC=CC=C2C1(C)C(=O)O[C@H](CC1)CC[C@@H]1N(C)CCCCCCCCCNC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 Chemical compound C12=CC=CC=C2OC2=CC=CC=C2C1(C)C(=O)O[C@H](CC1)CC[C@@H]1N(C)CCCCCCCCCNC[C@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2 WCRHWWWLTNWHQS-ABCZBHHISA-N 0.000 claims 1
- RFHUGEAREMSBLP-WBXFWKJNSA-N CN(CCC(NC(C=C(C(CNC[C@@H](C(C(C=C1)=C2NC1=O)=CC=C2O)O)=C1)OC)=C1Cl)=O)[C@H](CC1)CC[C@@H]1OC(C(O)=O)(C1=CC=CS1)C1=CC=CS1 Chemical compound CN(CCC(NC(C=C(C(CNC[C@@H](C(C(C=C1)=C2NC1=O)=CC=C2O)O)=C1)OC)=C1Cl)=O)[C@H](CC1)CC[C@@H]1OC(C(O)=O)(C1=CC=CS1)C1=CC=CS1 RFHUGEAREMSBLP-WBXFWKJNSA-N 0.000 claims 1
- AHZPWGGWOSEDTP-WBXFWKJNSA-N COc1cc(NC(=O)CCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 Chemical compound COc1cc(NC(=O)CCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)c(Cl)cc1CNC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 AHZPWGGWOSEDTP-WBXFWKJNSA-N 0.000 claims 1
- 208000020446 Cardiac disease Diseases 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- DEFIGYIWVLTMLO-GHAOVRLMSA-N F.CC(Cc1ccc(OCCCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 Chemical compound F.CC(Cc1ccc(OCCCN(C)[C@H]2CC[C@@H](CC2)OC(=O)C(O)(c2cccs2)c2cccs2)cc1)NC[C@H](O)c1ccc(O)c2[nH]c(=O)ccc12 DEFIGYIWVLTMLO-GHAOVRLMSA-N 0.000 claims 1
- LPRBLDKUDJHOFD-XFPMNCHFSA-N F.O([C@H]1CC[C@@H](CC1)N(C)CCCOC=1C=C(C(=CC=1Cl)CNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)OC)C(C(O)=O)(C=1SC=CC=1)C1=CC=CS1 Chemical compound F.O([C@H]1CC[C@@H](CC1)N(C)CCCOC=1C=C(C(=CC=1Cl)CNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)OC)C(C(O)=O)(C=1SC=CC=1)C1=CC=CS1 LPRBLDKUDJHOFD-XFPMNCHFSA-N 0.000 claims 1
- AOPUMVRFTQOFIF-ZJTCZQGWSA-N F.O([C@H]1CC[C@@H](CC1)N(CCC(=O)NC=1C(=CC(CNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)=CC=1)Cl)C)C(C(O)=O)(C=1SC=CC=1)C1=CC=CS1 Chemical compound F.O([C@H]1CC[C@@H](CC1)N(CCC(=O)NC=1C(=CC(CNC[C@H](O)C=2C=3C=CC(=O)NC=3C(O)=CC=2)=CC=1)Cl)C)C(C(O)=O)(C=1SC=CC=1)C1=CC=CS1 AOPUMVRFTQOFIF-ZJTCZQGWSA-N 0.000 claims 1
- CNLYMTUKZNDEKW-RGHVVQLISA-N F.O([C@H]1CC[C@@H](CC1)N(CCCOCCCCCCNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 Chemical compound F.O([C@H]1CC[C@@H](CC1)N(CCCOCCCCCCNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 CNLYMTUKZNDEKW-RGHVVQLISA-N 0.000 claims 1
- UTKFYKBUXIYENP-IYGAPYOLSA-N F.O([C@H]1CC[C@@H](CC1)N(CCOCCCCCCNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 Chemical compound F.O([C@H]1CC[C@@H](CC1)N(CCOCCCCCCNC[C@H](O)C=1C=2C=CC(=O)NC=2C(O)=CC=1)C)C(=O)C(O)(C=1SC=CC=1)C1=CC=CS1 UTKFYKBUXIYENP-IYGAPYOLSA-N 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 208000019693 Lung disease Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Rheumatology (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10382118A EP2386555A1 (en) | 2010-05-13 | 2010-05-13 | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| US36504510P | 2010-07-16 | 2010-07-16 | |
| EP11720386.9A EP2569308B1 (en) | 2010-05-13 | 2011-05-13 | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| PCT/EP2011/002376 WO2011141180A1 (en) | 2010-05-13 | 2011-05-13 | NEW CYCLOHEXYLAMINE DERIVATIVES HAVING β2 ADRENERGIC AGONIST AND M3 MUSCARINIC ANTAGONIST ACTIVITIES |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ME02675B true ME02675B (me) | 2017-06-20 |
Family
ID=42646365
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MEP-2017-18A ME02675B (me) | 2010-05-13 | 2011-05-13 | Novi derivati cikloheksilamina sa aktivnostima beta2 adrenergijskog agonista i m3 muscarinskog antagonista |
Country Status (38)
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| EP2592077A1 (en) * | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| EP2592078A1 (en) * | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| WO2014083171A1 (en) | 2012-11-30 | 2014-06-05 | Harmonic Pharma | Natural compounds for use in the treatment of beta-2 adrenergic receptor related diseases |
| AU2013360866A1 (en) | 2012-12-18 | 2015-07-02 | Almirall, S.A. | New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activity |
| TWI643853B (zh) * | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TW201440768A (zh) * | 2013-02-27 | 2014-11-01 | Almirall Sa | 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| EP3077386B1 (en) | 2013-12-05 | 2017-09-06 | Chiesi Farmaceutici S.p.A. | Benzhydryl derivatives for the treatment of respiratory diseases |
| KR20160086351A (ko) * | 2013-12-05 | 2016-07-19 | 키에시 파르마슈티시 엣스. 피. 에이. | 호흡기 질환의 치료를 위한 헤테로아릴 유도체 |
| EP3139924A4 (en) * | 2014-05-06 | 2018-03-07 | Anthony G. Visco | Methods of treating or preventing preterm labor |
| EP3152557A4 (en) | 2014-06-09 | 2017-12-13 | Biometry Inc. | Low cost test strip and method to measure analyte |
| US11175268B2 (en) | 2014-06-09 | 2021-11-16 | Biometry Inc. | Mini point of care gas chromatographic test strip and method to measure analytes |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
| TWI703138B (zh) * | 2015-02-12 | 2020-09-01 | 義大利商吉斯藥品公司 | 具有蕈毒鹼受體拮抗劑及β２腎上腺素受體促效劑活性之化合物 |
| AU2017300528C1 (en) | 2016-07-19 | 2022-10-20 | Biometry Inc. | Methods of and systems for measuring analytes using batch calibratable test strips |
| WO2020244452A1 (zh) * | 2019-06-06 | 2020-12-10 | 中国医药研究开发中心有限公司 | 具有β 2受体激动及M受体拮抗活性的杂环衍生物及其医药用途 |
| WO2022172296A1 (en) * | 2021-02-12 | 2022-08-18 | Gbr Laboratories Private Limited | A process for preparing navafenterol and intermediates thereof |
| WO2025245591A1 (en) * | 2024-05-31 | 2025-12-04 | Aché Laboratórios Farmacêuticos S.A. | Compounds, process for obtaining the compounds, intermediate compounds, reagent compounds, pharmaceutical compositions, pharmaceutical combinations, medicaments, uses and methods of treatment |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT7920688U1 (it) | 1979-02-05 | 1980-08-05 | Chiesi Paolo | Inalatore per sostanze medicamentose pulverulente, con combinata funzione di dosatore |
| ATE23272T1 (de) | 1981-07-08 | 1986-11-15 | Draco Ab | Pulverinhalator. |
| IT1212742B (it) | 1983-05-17 | 1989-11-30 | Dompe Farmaceutici Spa | Derivati dibenzo [1,4]diazepinonici pirido [1,4] benzodiazepinonici,pirido [1,5] benzodiazepinonici e loro attivita' farmacologica |
| US4570630A (en) | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
| DE3370320D1 (en) | 1983-09-26 | 1987-04-23 | Magis Farmaceutici | Aminocyclohexanol derivatives having an expectorant activity, process for their preparation and pharmaceutical compositions containing them |
| FI69963C (fi) | 1984-10-04 | 1986-09-12 | Orion Yhtymae Oy | Doseringsanordning |
| DE3927170A1 (de) | 1989-08-17 | 1991-02-21 | Boehringer Ingelheim Kg | Inhalator |
| EP1078629A3 (en) | 1989-09-07 | 2001-05-23 | Glaxo Group Limited | Use of Salmeterol and salts for the treatment of inflammation and allergy |
| IT1237118B (it) | 1989-10-27 | 1993-05-18 | Miat Spa | Inalatore multidose per farmaci in polvere. |
| US5201308A (en) | 1990-02-14 | 1993-04-13 | Newhouse Michael T | Powder inhaler |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| SG45171A1 (en) | 1990-03-21 | 1998-01-16 | Boehringer Ingelheim Int | Atomising devices and methods |
| GB9015522D0 (en) | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
| WO1992003175A1 (en) | 1990-08-11 | 1992-03-05 | Fisons Plc | Inhalation device |
| DE4027391A1 (de) | 1990-08-30 | 1992-03-12 | Boehringer Ingelheim Kg | Treibgasfreies inhalationsgeraet |
| GB9020051D0 (en) | 1990-09-13 | 1990-10-24 | Pfizer Ltd | Muscarinic receptor antagonists |
| DE69129188T2 (de) | 1990-09-26 | 1998-07-30 | Pharmachemie B.V., Haarlem | Inhalator mit einem reservoir für mehrere dosierte inhalationsmittel, mit transportvorrichtung und mit wirbelkammer |
| GB9026025D0 (en) | 1990-11-29 | 1991-01-16 | Boehringer Ingelheim Kg | Inhalation device |
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| DE4239402A1 (de) | 1992-11-24 | 1994-05-26 | Bayer Ag | Pulverinhalator |
| CA2152088C (en) | 1992-12-18 | 1999-12-07 | Thomas J. Ambrosio | Inhaler for powdered medications |
| JPH11509434A (ja) | 1995-04-14 | 1999-08-24 | グラクソ、ウェルカム、インコーポレーテッド | サルメテロール用計量投与用吸入器 |
| JP3299971B2 (ja) | 1995-06-21 | 2002-07-08 | アスタ メディカ アクチエンゲゼルシャフト | 一体的に形成された調量装置を備えた薬用粉末カートリッジおよび粉末薬剤吸入器 |
| DE19536902A1 (de) | 1995-10-04 | 1997-04-10 | Boehringer Ingelheim Int | Vorrichtung zur Hochdruckerzeugung in einem Fluid in Miniaturausführung |
| WO1998009632A1 (en) | 1996-09-06 | 1998-03-12 | Merck & Co., Inc. | Methods and compositions for treating preterm labor |
| JPH1171331A (ja) * | 1997-08-27 | 1999-03-16 | Tokyo Tanabe Co Ltd | アミノシクロアルキルメタノール化合物 |
| SE9704644D0 (sv) | 1997-12-12 | 1997-12-12 | Astra Ab | New use |
| US6673908B1 (en) | 1999-02-22 | 2004-01-06 | Nuvelo, Inc. | Tumor necrosis factor receptor 2 |
| BR0013469B1 (pt) | 1999-08-20 | 2011-01-25 | amidas aromáticas heterocìclicas fungicidas, composição fungicida compreendendo as mesmas, bem como método para o controle ou a prevenção de infestação fúngica. | |
| CZ20022410A3 (cs) * | 2000-01-31 | 2003-08-13 | Pfizer Products Inc. | Benzoanelované heterocyklylové deriváty nikotinamidu užitečné jako selektivní inhibitory isozymů PDE4 |
| CA2415468A1 (en) * | 2000-07-11 | 2003-01-10 | Yoshio Ogino | Ester derivatives |
| CN1250545C (zh) | 2000-12-28 | 2006-04-12 | 阿尔米雷尔普罗迪斯制药有限公司 | 新的奎宁环衍生物类及含有这类衍生物的药物组合物 |
| DE10129703A1 (de) | 2001-06-22 | 2003-01-02 | Sofotec Gmbh & Co Kg | Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren |
| DE10202940A1 (de) | 2002-01-24 | 2003-07-31 | Sofotec Gmbh & Co Kg | Patrone für einen Pulverinhalator |
| ES2195785B1 (es) | 2002-05-16 | 2005-03-16 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2211344B1 (es) | 2002-12-26 | 2005-10-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| PE20040950A1 (es) | 2003-02-14 | 2005-01-01 | Theravance Inc | DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS |
| WO2004089892A2 (en) | 2003-04-01 | 2004-10-21 | Theravance, Inc. | Diarylmethyl and related compounds having beta2 andrenergic receptor agonist and muscarinic receptor antagonist activity |
| ATE435862T1 (de) | 2003-05-28 | 2009-07-15 | Theravance Inc | Azabicycloalkanverbindungen als muscarinrezeptor antagonisten |
| ES2232306B1 (es) | 2003-11-10 | 2006-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| WO2005080375A1 (en) | 2004-02-13 | 2005-09-01 | Theravance, Inc. | Crystalline form of a biphenyl compound |
| DE102004024453A1 (de) | 2004-05-14 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue langwirksame Bronchodilatoren zur Behandlung von Atemwegserkrankungen |
| ES2251866B1 (es) | 2004-06-18 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| ES2251867B1 (es) | 2004-06-21 | 2007-06-16 | Laboratorios Almirall S.A. | Nuevos derivados de piridazin-3(2h)-ona. |
| RU2413544C2 (ru) | 2004-07-16 | 2011-03-10 | Алмиралл, С.А. | Ингалятор и картридж для лекарственного порошкового препарата и способ работы ингалятора |
| WO2006023460A2 (en) | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| WO2006023457A1 (en) | 2004-08-16 | 2006-03-02 | Theravance, Inc. | COMPOUNDS HAVING β2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY |
| TWI374883B (en) | 2004-08-16 | 2012-10-21 | Theravance Inc | Crystalline form of a biphenyl compound |
| EP1924553A1 (en) * | 2005-08-08 | 2008-05-28 | Argenta Discovery Limited | Bicyclo[2.2.]hept-7-ylamine derivatives and their uses |
| GB0602778D0 (en) | 2006-02-10 | 2006-03-22 | Glaxo Group Ltd | Novel compound |
| MX2008011963A (es) | 2006-03-20 | 2008-10-01 | Pfizer Ltd | Derivados de amina. |
| TW200811104A (en) | 2006-04-25 | 2008-03-01 | Theravance Inc | Crystalline forms of a dimethylphenyl compound |
| GB0613154D0 (en) | 2006-06-30 | 2006-08-09 | Novartis Ag | Organic Compounds |
| GB0702384D0 (en) * | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | Chemical compounds |
| WO2008017827A2 (en) | 2006-08-08 | 2008-02-14 | Argenta Discovery Limited | Azole and thiazole derivatives and their uses |
| EP1894568A1 (en) | 2006-08-31 | 2008-03-05 | Novartis AG | Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases |
| BRPI0719270A2 (pt) | 2006-10-04 | 2014-03-11 | Pfizer Ltd | Derivados de sulfonamida como agonistas adrenérgicos e antagonistas muscarínicos |
| GB0700972D0 (en) | 2007-01-18 | 2007-02-28 | Imp Innovations Ltd | Treatment of inflammatory disease |
| GB0702413D0 (en) | 2007-02-07 | 2007-03-21 | Argenta Discovery Ltd | New chemical compounds |
| WO2008096129A1 (en) | 2007-02-07 | 2008-08-14 | Argenta Discovery Ltd | Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors |
| WO2008149110A1 (en) | 2007-06-08 | 2008-12-11 | Argenta Discovery Limited | Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated |
| UY31235A1 (es) | 2007-07-21 | 2009-03-02 | Nuevos medicamentos pulverulentos que contienen tiotropio y salmeterol, asi como lactosa como excipiente | |
| WO2009017813A1 (en) | 2007-08-02 | 2009-02-05 | Teva Pharmaceutical Industries Ltd. | O-desmethyl venlafaxine saccharinate |
| KR101273200B1 (ko) | 2008-02-06 | 2013-06-17 | 펄마젠 쎄라퓨틱스 (시너지) 리미티드 | 화합물 |
| CN101544572B (zh) | 2008-03-26 | 2013-03-20 | 连云港恒邦医药科技有限公司 | 一种氨溴索衍生物及其制备方法 |
| GB0808708D0 (en) | 2008-05-13 | 2008-06-18 | Astrazeneca Ab | New compounds 274 |
| US8263623B2 (en) | 2008-07-11 | 2012-09-11 | Pfizer Inc. | Triazol derivatives useful for the treatment of diseases |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| PT2599778T (pt) | 2009-04-23 | 2017-06-06 | Theravance Respiratory Co Llc | Compostos de diamida possuindo actividade antagonista do receptor muscarínico e agonista do receptor adrenérgico beta 2 |
| WO2010126025A1 (ja) | 2009-04-30 | 2010-11-04 | 帝人ファーマ株式会社 | 四級アンモニウム塩化合物 |
| GB0913345D0 (en) | 2009-07-31 | 2009-09-16 | Astrazeneca Ab | New combination 802 |
| ITRM20110083U1 (it) | 2010-05-13 | 2011-11-14 | De La Cruz Jose Antonio Freire | Piastra per la costruzione di carrelli per aeroplani |
| EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
| AR083115A1 (es) | 2010-09-30 | 2013-01-30 | Theravance Inc | Sales oxalato cristalinas de un compuesto diamida |
| GB201021992D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | Compound |
| GB201021979D0 (en) | 2010-12-23 | 2011-02-02 | Astrazeneca Ab | New compound |
| HRP20151317T1 (hr) | 2011-06-10 | 2016-01-01 | Chiesi Farmaceutici S.P.A. | Spojevi koji pokazuju aktivnost prema antagonistima muskarinskog receptora i beta2 adrenergiäśnog receptora |
| RU2606121C2 (ru) | 2011-06-10 | 2017-01-10 | КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. | Соединения, обладающие антагонистической активностью в отношении мускариновых рецепторов и агонистической активностью в отношении бета2-адренорецепторов |
| EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
| GEP201706656B (en) | 2011-11-11 | 2017-04-25 | Pfizer | 2-thiopyrimidinones |
| ES2665580T3 (es) | 2011-11-11 | 2018-04-26 | Gilead Apollo, Llc | Inhibidores de ACC y usos de los mismos |
| UA111867C2 (uk) | 2011-11-11 | 2016-06-24 | Аллерган, Інк. | ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ І СПОСІБ ЗАСТОСУВАННЯ ПОХІДНИХ 4-ПРЕГНЕН-11β-17-21-ТРІОЛ-3,20-ДІОНУ |
| EP3345904B1 (en) | 2012-12-06 | 2020-07-29 | Chiesi Farmaceutici S.p.A. | Compounds having muscarinic receptor antagonist and beta2 adrenergic receptor agonist activity |
| KR102156441B1 (ko) | 2012-12-06 | 2020-09-17 | 키에시 파르마슈티시 엣스. 피. 에이. | 무스카린성 수용체 길항제 및 베타2 아드레날린성 수용체 효능제 활성을 가지는 화합물 |
| AU2013360866A1 (en) | 2012-12-18 | 2015-07-02 | Almirall, S.A. | New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activity |
| TW201440768A (zh) | 2013-02-27 | 2014-11-01 | Almirall Sa | 雙毒蕈鹼拮抗劑-β2腎上腺素促效劑複合物及皮質類固醇之組合物 |
| TWI643853B (zh) | 2013-02-27 | 2018-12-11 | 阿爾米雷爾有限公司 | 同時具有β2腎上腺素受體促效劑和M3毒蕈鹼受體拮抗劑活性之2-氨基-1-羥乙基-8-羥基喹啉-2(1H)-酮衍生物之鹽類 |
| TWI641373B (zh) | 2013-07-25 | 2018-11-21 | 阿爾米雷爾有限公司 | 具有蕈毒鹼受體拮抗劑和β２腎上腺素受體促效劑二者之活性的２－胺基－１－羥乙基－８－羥基喹啉－２（１Ｈ）－酮衍生物之鹽 |
| TW201517906A (zh) | 2013-07-25 | 2015-05-16 | Almirall Sa | 含有ｍａｂａ化合物和皮質類固醇之組合 |
| TW201617343A (zh) | 2014-09-26 | 2016-05-16 | 阿爾米雷爾有限公司 | 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物 |
-
2010
- 2010-05-13 EP EP10382118A patent/EP2386555A1/en not_active Withdrawn
-
2011
- 2011-04-28 UY UY33362A patent/UY33362A/es unknown
- 2011-05-09 TW TW100116155A patent/TWI526442B/zh not_active IP Right Cessation
- 2011-05-11 AR ARP110101622A patent/AR081387A1/es active IP Right Grant
- 2011-05-13 PL PL11720386T patent/PL2569308T3/pl unknown
- 2011-05-13 ME MEP-2017-18A patent/ME02675B/me unknown
- 2011-05-13 MY MYPI2012700932A patent/MY171899A/en unknown
- 2011-05-13 AU AU2011252337A patent/AU2011252337C1/en not_active Ceased
- 2011-05-13 DK DK11720386.9T patent/DK2569308T3/da active
- 2011-05-13 KR KR1020127029561A patent/KR101756497B1/ko not_active Expired - Fee Related
- 2011-05-13 NZ NZ602556A patent/NZ602556A/xx not_active IP Right Cessation
- 2011-05-13 EP EP11720386.9A patent/EP2569308B1/en active Active
- 2011-05-13 PH PH1/2012/502237A patent/PH12012502237A1/en unknown
- 2011-05-13 HU HUE11720386A patent/HUE033244T2/hu unknown
- 2011-05-13 EA EA201201541A patent/EA022358B1/ru not_active IP Right Cessation
- 2011-05-13 SI SI201131037A patent/SI2569308T1/sl unknown
- 2011-05-13 WO PCT/EP2011/002376 patent/WO2011141180A1/en not_active Ceased
- 2011-05-13 SM SM20170022T patent/SMT201700022T1/it unknown
- 2011-05-13 BR BR112012026570A patent/BR112012026570A2/pt not_active Application Discontinuation
- 2011-05-13 PE PE2012002162A patent/PE20130215A1/es active IP Right Grant
- 2011-05-13 CN CN201180023678.6A patent/CN102892765B/zh not_active Expired - Fee Related
- 2011-05-13 LT LTEP11720386.9T patent/LT2569308T/lt unknown
- 2011-05-13 RS RS20170180A patent/RS55725B1/sr unknown
- 2011-05-13 CA CA2799099A patent/CA2799099C/en active Active
- 2011-05-13 JP JP2013509473A patent/JP5851489B2/ja not_active Expired - Fee Related
- 2011-05-13 HR HRP20170307TT patent/HRP20170307T1/hr unknown
- 2011-05-13 MX MX2012012897A patent/MX2012012897A/es active IP Right Grant
- 2011-05-13 PT PT117203869T patent/PT2569308T/pt unknown
- 2011-05-13 ES ES11720386.9T patent/ES2613355T3/es active Active
- 2011-05-13 SG SG2012078689A patent/SG185007A1/en unknown
-
2012
- 2012-09-19 ZA ZA2012/07031A patent/ZA201207031B/en unknown
- 2012-10-03 EC ECSP12012213 patent/ECSP12012213A/es unknown
- 2012-10-18 IL IL222538A patent/IL222538A/en active IP Right Grant
- 2012-11-12 GT GT201200307A patent/GT201200307A/es unknown
- 2012-11-12 CL CL2012003171A patent/CL2012003171A1/es unknown
- 2012-11-13 CR CR20120574A patent/CR20120574A/es unknown
- 2012-11-13 CO CO12203219A patent/CO6592031A2/es active IP Right Grant
-
2016
- 2016-03-14 US US15/068,926 patent/US9643961B2/en not_active Expired - Fee Related
- 2016-12-19 CY CY20161101314T patent/CY1118352T1/el unknown
-
2017
- 2017-01-16 SM SM201700022T patent/SMT201700022B/it unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20170307T1 (hr) | NOVI DERIVATI CIKLOHEKSILAMINA KOJI POSJEDUJU DJELOVANJA AGONISTA ß2 ADRENERGIČKOG RECEPTORA I ANTAGONISTA M3 MUSKARINSKOG RECEPTORA | |
| ME02323B (me) | Spiro supstituisana jedinjenja kao inhibitori angiogeneze | |
| JP2013526494A5 (enExample) | ||
| JP2010528089A5 (enExample) | ||
| MA28598B1 (fr) | Combinaisons de glycopyrrolate et d'agonistes de recepteur beta2-adrenergique | |
| JP2008509166A5 (enExample) | ||
| RU2009109160A (ru) | Инсектицидные изоксазолины | |
| RU2008125196A (ru) | Новые производные тиофена | |
| JP2011529037A5 (enExample) | ||
| EA201001455A1 (ru) | Пиридины и пиразины в качестве ингибиторов pi3k (фосфатидилинозиткиназы-3) | |
| JP2016505582A5 (enExample) | ||
| HRP20120494T1 (hr) | Derivati purina za uporabu kao agonista adenozin a2a receptora | |
| WO2009109867A3 (en) | Crystal form of phenylamino pyrimidine derivative | |
| JP2011506494A5 (enExample) | ||
| MX2009010790A (es) | Derivados de heteroarilo biciclico fusionados. | |
| EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
| ME02697B (me) | Supstituisani biciklični dihidropirimidinoni i njihova primena kao inhibitori aktivnosti neutrofil elastaze | |
| JP2003306481A5 (enExample) | ||
| TWI440461B (zh) | １ｈ-喹唑啉-２，４-二酮 | |
| RU2015142383A (ru) | Новейшие антагонисты trpa1-рецепторов | |
| JP2012527487A5 (enExample) | ||
| JP2011500575A5 (enExample) | ||
| JP2016500115A5 (enExample) | ||
| EA200500095A1 (ru) | Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств | |
| BRPI0409374A (pt) | composto, composição farmacêutica, uso de pelo menos um composto, e, método para o tratamento de um distúrbio médico |